

Resource Summary Report

Generated by PRECISE-TBI on Jul 30, 2026

SARS-CoV Nucleoprotein / NP Antibody, Rabbit MAb

RRID:AB_2827974

Type: Antibody

Proper Citation

Sino Biological Cat# 40143-R001, RRID:AB_2827974

Antibody Information

URL: http://antibodyregistry.org/AB_2827974

Proper Citation: Sino Biological Cat# 40143-R001, RRID:AB_2827974

Target Antigen: Nucleoprotein

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: WB, ELISA, IHC-P, FCM, ICC/IF, IP

Antibody Name: SARS-CoV Nucleoprotein / NP Antibody, Rabbit MAb

Description: This monoclonal targets Nucleoprotein

Clone ID: Clone #001

Antibody ID: AB_2827974

Vendor: Sino Biological

Catalog Number: 40143-R001

Record Creation Time: 20250819T231957+0000

Record Last Update: 20250820T050118+0000

Ratings and Alerts

- Used for immuno staining assay by the Human Islet Research Network community. Contact(s): Xuming Tang, Skyler Uhl, Joshua Acklin - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for SARS-CoV Nucleoprotein / NP Antibody, Rabbit MAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Jung SF, et al. (2025) Direct interaction of HMGB1 with SARS-CoV-2 facilitates its infection via RAGE-dependent endocytosis. *iScience*, 28(8), 113063.

Thomas DeCruz A, et al. (2025) Quantum-enhanced nanodiamond rapid test advances early SARS-CoV-2 antigen detection in clinical diagnostics. *Nature communications*, 16(1), 8778.

Xing L, et al. (2025) Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target. *Cell*, 188(5), 1297.

Wei X, et al. (2025) Immune imprinting blunts omicron pathogenicity fluctuations and highlights the essential role of cellular immunity in SARS-CoV-2 infection. *Cell reports*, 44(6), 115784.

Yang L, et al. (2024) SARS-CoV-2 infection causes dopaminergic neuron senescence. *Cell stem cell*, 31(2), 196.

Kober DL, et al. (2024) Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2 in vivo. *mBio*, 15(6), e0076824.

Sasaki M, et al. (2024) Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in a COVID-19 hamster model. *EBioMedicine*, 99, 104950.

Dickey TH, et al. (2024) RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination. *Antiviral research*, 228, 105937.

Han S, et al. (2024) Host specific sphingomyelin is critical for replication of diverse RNA viruses. *Cell chemical biology*, 31(12), 2052.

Liu B, et al. (2024) An unconventional VH1-2 antibody tolerates escape mutations and shows an antigenic hotspot on SARS-CoV-2 spike. *Cell reports*, 43(6), 114265.

Wolff ASB, et al. (2023) Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. *iScience*, 26(7), 107084.

Kober DL, et al. (2023) Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2 in vivo. *bioRxiv : the preprint server for biology*.

Dickey TH, et al. (2023) Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines. *Cell reports*, 42(3), 112266.

Han Y, et al. (2022) A human iPSC-array-based GWAS identifies a virus susceptibility locus in the NDUFA4 gene and functional variants. *Cell stem cell*, 29(10), 1475.

Chong Z, et al. (2022) Nasally delivered interferon- γ protects mice against infection by SARS-CoV-2 variants including Omicron. *Cell reports*, 39(6), 110799.

Gorshkov K, et al. (2022) SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening. *ACS pharmacology & translational science*, 5(1), 8.

Zheng H, et al. (2022) Longitudinal analyses reveal distinct immune response landscapes in lung and intestinal tissues from SARS-CoV-2-infected rhesus macaques. *Cell reports*, 39(8), 110864.

Khan M, et al. (2022) Anatomical barriers against SARS-CoV-2 neuroinvasion at vulnerable interfaces visualized in deceased COVID-19 patients. *Neuron*, 110(23), 3919.

Li Z, et al. (2022) Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. *Cell metabolism*, 34(3), 424.

Khan M, et al. (2021) Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. *Cell*, 184(24), 5932.